144 related articles for article (PubMed ID: 10842400)
21. Abciximab offers greater benefits to insulin-dependent diabetic patients undergoing coronary stent implantation.
López-Mínguez JR; Nogales JM; González R; Palanco C; Doncel J; Vaello A; Giménez F; Morales A; Alonso R; Merchán A
Cardiovasc Revasc Med; 2007; 8(3):175-82. PubMed ID: 17765647
[TBL] [Abstract][Full Text] [Related]
22. Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation.
Velianou JL; Mathew V; Wilson SH; Barsness GW; Grill DE; Holmes DR
Am J Cardiol; 2000 Nov; 86(10):1063-8. PubMed ID: 11074200
[TBL] [Abstract][Full Text] [Related]
23. Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: results of the Diabetes Abciximab steNT Evaluation (DANTE) randomized trial.
Chaves AJ; Sousa AG; Mattos LA; Abizaid A; Staico R; Feres F; Centemero M; Tanajura LF; Abizaid A; Pinto I; Maldonado G; Seixas A; Costa MA; Paes A; Mintz GS; Sousa JE
Circulation; 2004 Feb; 109(7):861-6. PubMed ID: 14757690
[TBL] [Abstract][Full Text] [Related]
24. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
[TBL] [Abstract][Full Text] [Related]
25. [Adjuvant therapy with a glycoprotein IIb-IIa inhibitor (abciximab) in coronary angioplasties with a high thrombotic risk].
Matos V; Marques AM; Oliveira H; Ramos D; Lopes P; Camacho M; Gonsalves A
Rev Port Cardiol; 1998 Dec; 17(12):1001-5. PubMed ID: 9973861
[TBL] [Abstract][Full Text] [Related]
26. Clinical impact of abciximab on long-term outcome after complex coronary angioplasty.
Wijpkema JS; Jessurun GA; Van Boven AJ; Versteeg DI; Hautvast RW; Tio RA
Catheter Cardiovasc Interv; 2003 Nov; 60(3):339-43. PubMed ID: 14571484
[TBL] [Abstract][Full Text] [Related]
27. The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention.
Mayes CE; Kandzari DE; Goldschmidt-Clermont PJ; Phillips HR
J Invasive Cardiol; 2002 Dec; 14 Suppl E():36E-46E; quiz 47E. PubMed ID: 12668861
[TBL] [Abstract][Full Text] [Related]
28. Usefulness of abciximab for treatment of early coronary artery stent thrombosis.
Casserly IP; Hasdai D; Berger PB; Holmes DR; Schwartz RS; Bell MR
Am J Cardiol; 1998 Oct; 82(8):981-5. PubMed ID: 9794358
[TBL] [Abstract][Full Text] [Related]
29. Diabetes and coronary revascularization.
Flaherty JD; Davidson CJ
JAMA; 2005 Mar; 293(12):1501-8. PubMed ID: 15784875
[TBL] [Abstract][Full Text] [Related]
30. [Does abciximab improve the prognosis of diabetics after percutaneous coronary intervention?].
Hernández García JM; Domínguez Franco A; Jiménez-Navarro MF; Alonso Briales JH; Curiel Balsera E; Gómez Doblas JJ; De Teresa Galván E
Rev Esp Cardiol; 2002 Aug; 55(8):810-5. PubMed ID: 12199976
[TBL] [Abstract][Full Text] [Related]
31. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up.
Montalescot G; Antoniucci D; Kastrati A; Neumann FJ; Borentain M; Migliorini A; Boutron C; Collet JP; Vicaut E
Eur Heart J; 2007 Feb; 28(4):443-9. PubMed ID: 17251257
[TBL] [Abstract][Full Text] [Related]
32. Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel.
Schühlen H; Kastrati A; Mehilli J; Hausleiter J; Dirschinger J; Dotzer F; Bollwein H; Schömig A
Am Heart J; 2006 Jun; 151(6):1248-54. PubMed ID: 16781230
[TBL] [Abstract][Full Text] [Related]
33. The benefit of abciximab in percutaneous coronary revascularization is not device-specific.
Bhatt DL; Lincoff AM; Califf RM; Simoons ML; Tcheng JE; Brener SJ; Wolski KE; Topol EJ
Am J Cardiol; 2000 May; 85(9):1060-4. PubMed ID: 10781752
[TBL] [Abstract][Full Text] [Related]
34. [Role of glycoprotein IIb/IIIa inhibitors in the treatment of degenerated aortocoronary saphenous vein grafts].
Brück M; Ludwig J; Flachskampf FA; Daniel WG
Z Kardiol; 2002 Jan; 91(1):16-23. PubMed ID: 11963202
[TBL] [Abstract][Full Text] [Related]
35. Coronary artery bypass graft in abciximab-treated patients.
LeNarz LA
Ann Thorac Surg; 2000 Aug; 70(2 Suppl):S38-42. PubMed ID: 10966009
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
[TBL] [Abstract][Full Text] [Related]
37. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention.
Steinhubl SR; Kottke-Marchant K; Moliterno DJ; Rosenthal ML; Godfrey NK; Coller BS; Topol EJ; Lincoff AM
Circulation; 1999 Nov; 100(19):1977-82. PubMed ID: 10556224
[TBL] [Abstract][Full Text] [Related]
38. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
Tcheng JE
Am J Cardiol; 1996 Aug; 78(3A):35-40. PubMed ID: 8751845
[TBL] [Abstract][Full Text] [Related]
39. Optimizing the use of abciximab and intracoronary stents in patients with acute ST elevation myocardial infarction.
Velianou JL; Al-Suwaidi J; Mathew V
Am J Cardiovasc Drugs; 2002; 2(5):315-22. PubMed ID: 14727961
[TBL] [Abstract][Full Text] [Related]
40. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).
Stuckey TD; Stone GW; Cox DA; Tcheng JE; Garcia E; Carroll J; Guagliumi G; Rutherford BD; Griffin JJ; Turco M; Lansky AJ; Mehran R; Fahy M; Brodie BR; Grines CL;
Am J Cardiol; 2005 Jan; 95(1):1-7. PubMed ID: 15619385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
